secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001628280-26-001767
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions reports preliminary Q4 2025 revenue $24.8M (+20% YoY); FY 2025 revenue $96.2M beats raised guidance
--------------------------------------------------------------------------------

- Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.
- FY 2025 revenue $96.2M, up 29% from $74.6M in 2024, exceeding raised guidance of $95-96M.
- Q4 revenue excludes ~$1.3M in biopreservation revenue shifted to Q3 at customer request.
- CEO notes evo divestiture complete; company now pure-play cell processing with recurring revenue.
- Expects 2026 revenue growth and adjusted EBITDA margin expansion; full guidance in Feb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828026001767/0001628280-26-001767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828026001767/blfs-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer